# Relapsed/Refractory Mantle Cell Lymphoma FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/relapsed-refractory-mantle-cell-lymphoma

> No upcoming FDA catalysts in Relapsed/Refractory Mantle Cell Lymphoma; 3 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for Relapsed/Refractory Mantle Cell Lymphoma?

No upcoming FDA catalysts in Relapsed/Refractory Mantle Cell Lymphoma; 3 past events are recorded. ClinicalTrials.gov: "NCT04880434 (Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-17 (ACTUAL); Lead Sponsor Kite, A Gilead Company; Results First Posted 2026-08-18." [Calendar and source filings](https://sec-api.dev/indications/relapsed-refractory-mantle-cell-lymphoma)

Source: ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT04880434?tab=results (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/indications/relapsed-refractory-mantle-cell-lymphoma#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 17, 2025 | [Fludarabine primary completion](https://sec-api.dev/pdufa/fludarabine) | GILD | Relapsed/Refractory Mantle Cell Lymphoma | completed | "NCT04880434 (Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-17 (ACTUAL); Lead Sponsor Kite, A Gilead Company; Results First Posted 2026-08-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04880434)) |
| August 29, 2025 | [BEQALZI™ (sonrotoclax) topline data readout](https://sec-api.dev/pdufa/sonrotoclax) | ONC | relapsed/refractory mantle cell lymphoma | completed, positive | "On August 29, 2025, we announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory mantle cell lymphoma, following treatment with a Bruton's tyrosine kinase inhibitor ("BTKi") and anti-CD20 therapy." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1651308/000162828025049824/bgne-20250930.htm)) |
| August 18, 2026 | [Fludarabine topline data readout](https://sec-api.dev/pdufa/fludarabine) | GILD | Relapsed/Refractory Mantle Cell Lymphoma | completed | "NCT04880434 (Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-17 (ACTUAL); Lead Sponsor Kite, A Gilead Company; Results First Posted 2026-08-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04880434?tab=results)) |

## Drugs

- [Fludarabine](https://sec-api.dev/pdufa/fludarabine) (GILD)
- [BEQALZI™ (sonrotoclax)](https://sec-api.dev/pdufa/sonrotoclax) (ONC)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/relapsed-refractory-mantle-cell-lymphoma.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Relapsed/Refractory Mantle Cell Lymphoma FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/relapsed-refractory-mantle-cell-lymphoma

```bibtex
@misc{secapidev_indications_relapsed_refractory_mantle_cell_lymphoma_20261116,
  title        = {Relapsed/Refractory Mantle Cell Lymphoma FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/relapsed-refractory-mantle-cell-lymphoma}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_relapsed_refractory_mantle_cell_lymphoma_20261116","title":"Relapsed/Refractory Mantle Cell Lymphoma FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/relapsed-refractory-mantle-cell-lymphoma","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
